Hanmi Pharmaceutical’s domestically developed GLP-1 obesity drug eppe (efpeglenatide) was listed on the Korean telemedicine platform Doctornow at roughly 160,000 to 200,000 won for the first month of treatment, according to Doctornow listings reported Monday, making it 26 to 30 percent cheaper than Wegovy (semaglutide) and 41 to 44 percent cheaper than Mounjaro (tirzepatide) at clinics in Seoul and Gyeonggi Province. The listing followed Hanmi’s launch of eppe on Thursday, after Korean approval on Oct. 7, and marks the first domestically developed GLP-1 obesity treatment to reach the Korean market.
The price gap matters well beyond Korea’s borders. GLP-1 receptor agonists have become the fastest-growing category in peptide-based medicine, and the first-month list price a manufacturer can defend at the clinic level shapes how telehealth platforms, compounding pharmacies and peptide therapy operators build their own cost structures. For clinics and telemedicine businesses that quote monthly out-of-pocket figures to patients, a domestic entrant priced a third below imported brands resets the reference point that every competing product, including compounded semaglutide and tirzepatide, will be measured against.
What happened: eppe enters the Korean GLP-1 market at a discount
Hanmi Pharmaceutical received Korean regulatory approval for eppe on Oct. 7 and launched the product on Thursday, according to the company’s timeline reported by Korea Biomedical Review. Doctornow, a Korean telemedicine app that also lets users compare drug prices and book in-person visits at partner clinics, displayed eppe first-month pricing at partner clinics in Seoul and Gyeonggi Province on Monday.
The first-month regimen is split across two dose strengths. Two eppe 2 mg pens, used during the first two weeks of treatment, were generally listed at around 60,000 to 80,000 won, while two 4 mg pens, used in weeks three and four, were mostly priced at around 100,000 to 120,000 won. Together they produce the 160,000 to 200,000 won first-month range.
For comparison, Doctornow showed the Wegovy 0.25 mg starting dose at about 228,000 to 270,000 won for four weeks, and the Mounjaro 2.5 mg starting dose at roughly 288,000 to 340,000 won for four weeks. At the low end, eppe’s 160,000 won first-month price sits 30 percent below Wegovy’s lowest listed price and 44 percent below Mounjaro’s; at the high end, 200,000 won is 26 percent below Wegovy’s highest listed price and 41 percent below Mounjaro’s.
Key numbers: first-month GLP-1 prices on Doctornow
| Product (starting phase) | First-month list price (won) | Approx. US dollars | Gap vs. eppe |
|---|---|---|---|
| eppe (efpeglenatide), 2 mg then 4 mg | 160,000–200,000 | ~$120–$150 | — |
| Wegovy (semaglutide), 0.25 mg | 228,000–270,000 | ~$170–$202 | eppe 26–30% lower |
| Mounjaro (tirzepatide), 2.5 mg | 288,000–340,000 | ~$215–$254 | eppe 41–44% lower |
Two caveats belong next to those figures. Prices are set by individual medical institutions and may vary by clinic or hospital, so the Doctornow ranges are not national averages. And the three drugs follow different dose-escalation schedules, which means first-month prices do not directly show their longer-term treatment costs.
Why the price gap matters for peptide therapy and research peptide markets
The comparison is a first-month snapshot, not a cost-of-therapy verdict. eppe starts at 2 mg once weekly for two weeks, rises to 4 mg for another two weeks, then moves to 6 mg once weekly for four weeks and 8 mg for four weeks, with a maintenance dose of 10 mg once weekly. Wegovy begins at 0.25 mg once weekly for four weeks and escalates every four weeks through 0.5 mg, 1 mg and 1.7 mg to a recommended maintenance dose of 2.4 mg. Mounjaro starts at 2.5 mg once weekly, rises to 5 mg after four weeks, and can increase in 2.5 mg steps after at least four weeks at the current dose, up to a maximum approved dose of 15 mg once weekly.
Because each product reaches its maintenance dose on a different timetable, the month-one figure understates or overstates total course cost depending on the molecule. Industry observers note that payers and clinic operators typically compare cost per patient per year at maintenance dose, not entry pricing. The available evidence does not yet establish how eppe’s full-course cost will compare with either imported brand.
All three treatments are currently paid for out of pocket when prescribed for obesity in Korea. Novo Nordisk has applied for reimbursement for Wegovy for certain patients with severe obesity and comorbidities, and Lilly Korea is separately seeking reimbursement for Mounjaro in type 2 diabetes. Neither application has been decided, so the current out-of-pocket comparison could shift if reimbursement is granted.
Supply chain and clinic operations: what a domestic entrant changes
For peptide therapy clinics, medical spas and telemedicine operators, list price is only one line in the cost model. The rest sits in procurement: which finished-product SKUs are available, in what container format, with what batch documentation, and at what landed cost after cold-chain shipping and customs clearance. A domestically manufactured GLP-1 pen removes cross-border freight, import clearance and currency exposure from the Korean supply chain, which is one structural reason a local entrant can price below imported rivals.
That logic travels. Clinics sourcing peptide products internationally, whether finished pens, vials or dual-chamber cartridges, generally evaluate a supplier on batch-specific certificates of analysis, identity and purity testing by HPLC and LC-MS, impurity profiles, storage requirements and traceability. A certificate of analysis reports specified analytical results for a batch; it does not by itself establish clinical safety, efficacy or regulatory approval. Buyers who treat a COA as a safety guarantee are misreading the document.
This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com. PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates. Operators tracking how list prices translate into procurement decisions can follow supplier and logistics intelligence through peptidescm and PeptideDDP.
Research and market context: GLP-1 pricing as a competitive lever
Efpeglenatide is a GLP-1 receptor agonist, the same receptor class targeted by semaglutide, while tirzepatide activates both GIP and GLP-1 receptors. The approved products, indications, dosing, contraindications and labeling differ by molecule, and clinical decisions should rest on the relevant product labeling and professional evaluation rather than on price alone.
The Korean launch illustrates a broader pattern in peptide therapeutics: as more manufacturers master GLP-1 synthesis and pen assembly, competition migrates from molecule novelty toward manufacturing cost, device quality and distribution reach. A domestic producer that controls API supply, fill-finish and pen assembly can compress the price ladder faster than an importer that carries freight, tariffs and multi-tier distribution margins. Whether that compression reaches patients depends on clinic pricing behavior and on reimbursement policy, neither of which is settled.
For research peptide suppliers and API manufacturers, the signal is about volume and specification. GLP-1 demand at consumer scale pulls through requirements for high-purity API, consistent batch-to-batch quality and validated analytical methods. It also raises the bar on documentation, because clinic buyers increasingly ask for the same traceability from a peptide supplier that they expect from a pharmaceutical manufacturer.
What comes next
Three data points will determine whether eppe’s entry price holds as a durable advantage. First, whether the listed 160,000 to 200,000 won range survives beyond the launch window, given that individual institutions set their own prices. Second, how Novo Nordisk’s Wegovy reimbursement application for severe obesity with comorbidities and Lilly Korea’s Mounjaro reimbursement bid in type 2 diabetes are decided; either outcome would change relative out-of-pocket costs. Third, whether Hanmi discloses maintenance-dose pricing, which is the figure that actually determines annual treatment cost.
Until then, the defensible reading is narrow: at the clinics listed on Doctornow in Seoul and Gyeonggi Province on Monday, eppe’s first-month list price range was below the first-month list price ranges for Wegovy and Mounjaro. Claims that eppe is cheaper across a full course of treatment are not supported by the available evidence, and the source reporting explicitly cautions against that inference.
FAQ
How much does the first month of eppe cost in Korea?
Doctornow listings showed the first month of eppe at about 160,000 to 200,000 won at clinics in Seoul and Gyeonggi Province, comprising two 2 mg pens at roughly 60,000 to 80,000 won and two 4 mg pens at roughly 100,000 to 120,000 won.
Is eppe cheaper than Wegovy and Mounjaro?
For the first month of treatment at the listed clinics, yes: eppe was 26 to 30 percent below Wegovy and 41 to 44 percent below Mounjaro. Because the three drugs escalate doses on different schedules, first-month prices do not directly show longer-term treatment costs.
Is eppe approved by the FDA?
No. eppe received Korean approval on Oct. 7 and launched in Korea on Thursday. Approval status must be checked for each specific product, formulation and market; a Korean approval does not confer U.S. authorization.
Are these GLP-1 drugs covered by insurance in Korea?
All three are currently paid out of pocket when prescribed for obesity. Novo Nordisk has applied for Wegovy reimbursement for certain patients with severe obesity and comorbidities, and Lilly Korea is seeking Mounjaro reimbursement in type 2 diabetes; both applications are pending.
Comments